B. Riley Wealth Advisors Inc. Purchases 1,016 Shares of Centene Co. (NYSE:CNC)

B. Riley Wealth Advisors Inc. grew its position in Centene Co. (NYSE:CNC) by 32.4% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 4,152 shares of the company’s stock after purchasing an additional 1,016 shares during the quarter. B. Riley Wealth Advisors Inc.’s holdings in Centene were worth $307,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds have also modified their holdings of the company. Park Place Capital Corp boosted its position in shares of Centene by 1,190.0% in the third quarter. Park Place Capital Corp now owns 387 shares of the company’s stock worth $29,000 after purchasing an additional 357 shares during the period. WR Wealth Planners LLC boosted its position in shares of Centene by 41.4% in the second quarter. WR Wealth Planners LLC now owns 468 shares of the company’s stock worth $31,000 after purchasing an additional 137 shares during the period. Chris Bulman Inc purchased a new position in shares of Centene in the second quarter worth $33,000. Crewe Advisors LLC lifted its holdings in shares of Centene by 174.3% in the second quarter. Crewe Advisors LLC now owns 683 shares of the company’s stock worth $45,000 after buying an additional 434 shares in the last quarter. Finally, Private Trust Co. NA lifted its holdings in shares of Centene by 75.3% in the third quarter. Private Trust Co. NA now owns 773 shares of the company’s stock worth $58,000 after buying an additional 332 shares in the last quarter. 93.63% of the stock is currently owned by institutional investors.

Centene Trading Down 0.2 %

CNC stock opened at $59.58 on Friday. The company has a quick ratio of 1.10, a current ratio of 1.10 and a debt-to-equity ratio of 0.64. Centene Co. has a twelve month low of $55.03 and a twelve month high of $81.42. The stock has a market capitalization of $30.08 billion, a price-to-earnings ratio of 10.34, a price-to-earnings-growth ratio of 0.78 and a beta of 0.46. The firm’s fifty day simple moving average is $60.75 and its two-hundred day simple moving average is $68.21.

Insider Buying and Selling at Centene

In related news, Director H James Dallas purchased 1,693 shares of the business’s stock in a transaction dated Monday, December 16th. The shares were purchased at an average cost of $59.01 per share, for a total transaction of $99,903.93. Following the completion of the acquisition, the director now owns 1,693 shares in the company, valued at approximately $99,903.93. This trade represents a ∞ increase in their position. The purchase was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, Director Theodore R. Samuels II purchased 5,000 shares of the business’s stock in a transaction dated Friday, December 13th. The stock was bought at an average price of $58.86 per share, for a total transaction of $294,300.00. Following the completion of the acquisition, the director now owns 23,000 shares of the company’s stock, valued at approximately $1,353,780. The trade was a 27.78 % increase in their position. The disclosure for this purchase can be found here. Insiders have bought 45,010 shares of company stock worth $2,660,276 over the last quarter. Insiders own 0.33% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms have recently commented on CNC. Stephens lowered their target price on shares of Centene from $75.00 to $73.00 and set an “equal weight” rating on the stock in a report on Friday, December 13th. Cantor Fitzgerald reissued an “overweight” rating and issued a $90.00 target price on shares of Centene in a report on Wednesday, December 11th. Barclays boosted their target price on shares of Centene from $91.00 to $93.00 and gave the stock an “overweight” rating in a report on Friday, December 13th. Truist Financial decreased their price target on shares of Centene from $89.00 to $84.00 and set a “buy” rating on the stock in a research note on Friday, December 13th. Finally, Robert W. Baird decreased their price target on shares of Centene from $83.00 to $66.00 and set a “neutral” rating on the stock in a research note on Friday, October 25th. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating and ten have assigned a buy rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $80.92.

About Centene

Centene Corporation operates as a healthcare enterprise that provides programs and services to under-insured and uninsured families, commercial organizations, and military families in the United States. The company operates through Medicaid, Medicare, Commercial, and Other segments. The Medicaid segment offers health plan coverage, including medicaid expansion, aged, blind, disabled, children’s health insurance program, foster care, medicare-medicaid plans, long-term services and support.